|
|
| | (1S,2R,3R)-Aprepitant Basic information |
| Product Name: | (1S,2R,3R)-Aprepitant | | Synonyms: | Aprepitant Impurity 7;5-[[(2R,3R)-2-[(1S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one;Aprepitant (S,R,R)-Isomer;(2R,3R,1’S)-Aprepitant;Aprepitant iMpurity 31;Aprepitant Impurity 4(S,R,R-Isomer);Aprepitant impurity 8/(1S,2R,3R)-Aprepitant;5-([(2R,3R)-2-((S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluoro phenyl)morpholino]methyl)-1H-1,2,4-triazol-3(2H)-one | | CAS: | 1242175-34-3 | | MF: | C23H21F7N4O3 | | MW: | 534.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1242175-34-3.mol |  |
| | (1S,2R,3R)-Aprepitant Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | pka | 8.06±0.20(Predicted) |
| | (1S,2R,3R)-Aprepitant Usage And Synthesis |
| Uses | (2R,3R,1’S)-Aprepitant is an impurity of Aprepitant (A729800); a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic. |
| | (1S,2R,3R)-Aprepitant Preparation Products And Raw materials |
|